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Background: Clinical trials are critical to scientiﬁcally evaluate promising new therapies in oncology, but
patient accrual to these studies is persistently low. Patient preference plays an important role in
enrollment in these trials. We performed this survey to evaluate the perceptions of newly diagnosed
oncology patients about clinical trials and the reasons why they wish to or not to participate in these
trials.
Methods: Patients were given a ten question survey reﬂective of their attitudes regarding clinical trials as
a treatment option at their initial visit. The self-directed questionnaire was scored on an ordinate scale
from strongly agree [1] to strongly disagree [5].
Results: Ninety three patients were surveyed in the cancer speciﬁc multispecialty clinics in an academic
center. Our patients expected their providers to discuss all information relating to clinical trials and
eligibility at the ﬁrst visit (65.4% agree and 15.4% neutral, p < 0.0001). Patients felt their privacy and
safety would be safeguarded in the University sponsored trials (56.8% agree, and 25.7% neutral,
p < 0.0001). Over 80% patients showed their unwillingness to participate in randomized clinical trials
(disagree 61%, neutral 19.5%, p < 0.001). Patients also showed less likelihood to participate in clinical
trials as a ﬁrst treatment option (48.7% disagree and 28.9% neutral, p0.0161), but were willing to consider
participating in a clinical trial if the conventional treatment failed. Industry sponsored trials, phase 1
trials, investigator initiated trials with the involved tests and time commitment and altruistic reasons did
not signiﬁcantly deviate from the mean preference analyzed using Fisher's exact test analysis.
Conclusions: Patients consider the option of clinical trials as important in their treatment, and expect to
be informed by their oncologist about such trials. Newly diagnosed cancer patients perceive randomi-
zation and ﬁrst line trials negatively. Since randomization data provides new standards of care and hope
for improved treatment, patients and their families must be educated of their importance.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The efﬁcacy of new cancer treatments can only be reasonably
conﬁrmed through carefully designed prospective clinical trials. A
key requirement in the conduct of these trials is the enrollment of
sufﬁcient numbers of participants to establish adequate statistical
power and make it applicable to the intended population. In
addition, clinical trials offer cancer patients access to innovative
therapeutic approaches and have the potential of improving clinical
outcomes. A meta-analysis done in the past has shown that
centralized referral or entry into clinical trials was frequently
associatedwith higher survival rate [1]. However only a few eligible
cancer patients are recruited to clinical trials [2e4]. This obvious(G.H. Kloecker).
r Inc. This is an open access articlethreat to timely completion leads to delays and decreased access to
effective treatment plans.
It has been estimated that less than 5% of cancer patients
worldwide are enrolled in clinical trials [5]. In addition only
approximately half of these clinical trials reach the designated
minimum accrual numbers [6]. A recently published review from
Australia recognizes that only 2e3% of adult cancer patients partic-
ipate in clinical trials compared with 50% of pediatric patients [7].
This review critically analyses three main obstacles-clinician, patient
and system. Clinician behavior is the most important of these with
the observational studies suggesting clinicians may not be offering
participation to a large proportion of patients they know to be
eligible [7]. Lack of awareness of trials is the other common obstacles
to accrual [8e10]. Communication between clinician and patient
appears to be a greater issue than previously recognized. The most
contentious issue is still the potential beneﬁt of participation to an
individual patient. There have been three recent systematic reviewsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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beneﬁt [1,11,12]. Arguably, the most complete of these found that
evidence of beneﬁt was greater in childhood cancer, hematological
malignancies and for trials conducted before 1986 [11].
We conducted this trial with a primary objective to establish
patient's perspectives on participating in clinical trials. Initially we
discussed the importance of clinical trials in developing new drugs
for treatment of cancers, and cancer related events and their
understanding of what it means to them to participate in the trials
alongwith their expectations from the trials. Our survey constitutes
a better understanding with regards to beliefs and myths of
participating in trials. We hope these ﬁndings will provide more
insight to theoncologypractitioners tooptimallydevise a strategy to
improvepatient recruitment to improve accrual rates in future trials.
2. Methods
A single institution cross sectional study design was employed,
using a set of questionnaires developed to capture the trials related
attitudes and opinions of patients. The study was performed at the
James Graham Brown Cancer Center, part of the University of
Louisville Hospitals in Kentucky. The study had the institutional
review board approval and was performed fromMarch 2012 over a
one year period. Questionnaires were developed for patients to
examine their attitudes and beliefs regarding the various issues
surrounding the process of trial recruitment. First a literature
search was performed to identify factors previously reported to
inﬂuence patients' decision of participating in clinical trials.
2.1. Data collection
We surveyed cancer patients diagnosed with all non-
hematological malignancies for one year beginning March 2012.
The eligibility criteria included [1], age 18 years or older [2],
histological conﬁrmation of a solid tumor [3], life expectancy over 2
months and [4] an Eastern Cooperative oncology group (ECOG)
performance status of 0e2. . Patients who already had initiated
treatment were excluded. Physician consent was obtained prior to
patient enrollment. Written consent to participate in the study was
then obtained from the patients.
One well trained research nurse explained the purpose of the
survey and received written informed consent from all participants
before they were enrolled in the study. With the agreement of the
participants, clinical information of each patient was collected from
the medical records as and when needed. The study design and
survey instruments were approved by the Institutional Review
Board, University of Louisville Hospital.
2.2. Questionnaire
Patients reported their age, gender, level of education, ethnicity
and living status. The type of cancer and the stage was recorded by
the interviewer. Education was recorded as the highest grade
obtained at the time of diagnosis. All information was kept
conﬁdential.
The standardized self eadministered questionnaire consisted of
15 questions developed in collaboration with the biostatistics
department and the clinical trial division at James Graham Brown
Cancer center. Five questions concerned demographics that included
age, sex, ethnicity, gender and educational level. The remaining 10
questions asked about the cancer clinical trial understanding and
their perception. A score between 0 and 5 was used in the survey to
evaluate each of the 10 questions. A score of 1 indicated “agree
strongly” and 5 indicated “disagree strongly”. The questionnaire
format is described in the attached addendum (addendum 1).2.3. Statistical methods
All data generated was centrally reviewed and analyzed using
the Fisher's exact test to examine whether the response variable is
associated with each covariate, such as gender, age, cancer type,
ethnicity and education level and the p values obtained. A
biostatistician was consulted for all statistical designs and analyses
and all tests were considered statistically signiﬁcant at a p < 0.05.
3. Results
From March 1, 2012 to April 30 2013, a total of 93 patients were
asked to participate in the study, and 85 patients (93.41%) agreed to
complete the questionnaire. Four patients declined to participate
and four returned the questionnaire incomplete. The median age of
the cohort was 60 years with a range of 29e84 years. The groupwas
matched for sex distribution with 45 males (51.14%) and 43
(48.86%) females. 81% patients interviewed were Caucasians. Over
90% of the enrolled patients were educated to higher than 8th
grade, with 40% reporting college or postgraduate qualiﬁcation. 37
(41.6%) were involved in decisions for lung cancer trials, 20 (22.5%)
in melanoma cancer trials, 14 (15.7%) in breast cancer trials and
remainder in colorectal, pancreatic and other cancers.
Over 80% patientswanted their treating physician to inform them
about the ongoing clinical trials and their eligibility (51, (65.4%) agree
and 12 (15.4%) were neutral), with only 15 (19%) not wanting to
know of the trials, making this statistically signiﬁcant (p < 0.0001).
There was no difference based on the gender, level of education or
type of cancer regarding this although only 50% of African Americans
were interested to know of the trials (6 of the 12 patients). 83% of the
patients (42 (56.8% agree, 19, (25.7% neutral) agreed that the Uni-
versity sponsored clinical trials were protective of their privacy and
identity. This also reﬂected in the opinion on safety where 78% of the
patients (38 agreed and 19 were neutral) opined to be safe in a trial
sponsored by the University. Chi-square test done to test indepen-
dence of safety and privacy maintenance of trials conducted by the
University showed no statistical relationship.
On the other hand patients indicated a strong level of
disagreement of participating in randomized trials (“if enrolled in a
clinical trial, I am comfortable being assigned by a method such as
ﬂipping a coin or throwing a dice) with 80% (47 (61%) disagree and
15(19.5%) neutral) unwilling to participate in randomized trials,
and this was statistically signiﬁcant (p < 0.0001). In addition
signiﬁcant number of patients did not agree to consider partici-
pating in phase 1 trials as a ﬁrst treatment option (37 (48.7%)
disagree and 22 (28.9%) neutral). However over 67% of patients (33
(42.9%) agree and 23 (29.9%) neutral) were willing to consider
participating in a clinical trial if the conventional treatment failed.
Other factors which inﬂuenced decision making in participating
in clinical trials were if the trials were sponsored by drug
companies. In this regard, where majority of the patients were
neutral or undecided, 34 (46.6%) and 13 (17.8%), not willing to
participate in drug company sponsored trials. Mixed responses
were obtained with beneﬁts and risks involved with the phase 1
drugs when questioned - “I am less likely to participate in a clinical
trial if I might receive a promising new drug even if its positive and
negative effects are uncertain”. Equal number 28 (36.4%) patients
agreed or disagreed for participation with another 21 (27.3%) were
neutral or undecided. Finally with regards to altruistic behavior
pattern signiﬁcant number of patients agreed or remained neutral
33 (42.9%) and 25 (32.5%) as against 19 (24.7%)who disagreed. Most
patients did not mind the time and additional tests required with
the clinical trials, 30 (40%) agreed and 20 (26.7%) were neutral
versus 25 (33%) who were not willing to spend time and do addi-



































Fig. 1. Response Proﬁles for 10 Survey Questions. Inform (Q3), Privacy (Q9), Safety
(Q10), SLT (Second Line Treatment, Q6), Altruism (Q7), IE (Increased Effort, Q8), Phase I
(Q2), DC (Drug Companies, Q1), FTO (First Treatment Option, Q5), RT (Randomized Trial,
Q4). The responses of ﬁrst three questions are signiﬁcant different from the last three
(Inform & RT: p < 0.0001, Privacy & FTO: p < 0.0001, Safety & DC: p ¼ 0.0299).
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Our study is an attempt to identify the opinions and attitudes of
patients and their expectations about the beneﬁts of participating
in clinical trials. In particular we examined patients perceptions
with regards to information relating to the available trials, drug
company sponsored trials as against University sponsored trials,
trial conﬁdentiality and safety issues, chance of beneﬁt from the
experimental agent to self or to others, and their overall perception
of clinical trials.
The predictors identiﬁed in this study are not unique, but they do
present possible targets for intervention for increased patient accrual
in clinical trials. Overwhelming majority of our patients wanted in-
formation on the prevailing clinical trials and their eligibility. We
know that effective patient-physician communication is critical for
patient accrual in clinical trials. Past studies have shown that patients
want a high degree of information and the information usually
produces a positive effect [13]. Recent study has shown that the
attitude of patients is generally in favor of participation in clinical
trials and good communication with the treating physician plays a
dominant role in decisionmaking [14]. Past surveys have also shown
physicians underestimate patients' ability to comprehend and desire
to obtain information [14]. It is also known that physicians have
difﬁculties in estimating the amount and type of information that
patients want and their effectiveness in imparting information [15].
It then becomes the primary responsibility of the physician to impart
factual, reasonable and appropriate information so that the patient is
appropriately informed and enabled to make reasonable decisions
relative to treatment options.
Recent studieshave shownthere is anoverall increased awareness
regarding clinical trials between 2008 and 2012, although large sec-
tion of population still lacks general awareness [16]. Racial and ethnic
disparities in trial awareness exist although disparities may be
decreasing among the minorities [16]. However despite this aware-
ness there appears a reluctance to participate in a clinical trial as the
ﬁrst treatment option as evidenced in our study. There are many
reasons for this perception. Studies in the past have shown that some
patients thought that they would be used as “guinea pigs”, that pro-
posedparticipation inaclinical trialwas for the soleeconomic interest
of the physician and that physicians propose clinical trials even if
there are other drugs that could bemore effective than the drug used
in clinical trial [17]. Although patients have these concerns they are
not discussed during the conversation with the doctor, who is
concentrated onexplaining theproposed study; furthermore theyare
not usually cited in the informed consent and patients do not request
discussion of these concerns [18,19]. This could have the consequence
that patients, not having discussed and clariﬁed these issues, could be
inﬂuenced by them when making their decision whether or not to
participate in the proposed study,without being able to decide on the
objective reality of the study itself and in the ﬁnal analysis, without
being able tomakeeither a freeoran informeddecision [20].Weneed
to remember several studies in the past have shown patients
perception of personal beneﬁt to be the best predictor of clinical trial
entry [21]. We strongly recommend patients should have an open
discussion about the beneﬁts as well as risks of then participating in
trials and all concerns expressed by them to be duly addressed. We
need to highlight here that majority of our patients were willing to
consider participating in clinical trials if the conventional therapies
fail and/or if there are no other suitable alternatives.
Randomization is one of the most common protocol related
barriers to participation [22,23]. Our study conﬁrmed this ﬁnding
wherein more than 80% of our patients were not keen to participate
in randomized controlled trials. Researchers in the past have tried
to deduce reasons for poor accrual and perhaps random allocation
of treatment is a major reason why patients chose not to joinrandomized clinical trials [24,25]. Other reasons include a poor
understanding of the rationale for randomization as a method of
treatment allocation [25,26], and difﬁculty to comprehend the
complex terms used such as blinding or placebo [22]. Studies also
suggest, patients want to be actively involved in clinical decision
making and they prefer either the doctor or themselves tomake the
decision about which treatment they will receive [27,28]. Other
factors reported in the literature to be inﬂuential in patients'
decision to participate in randomized clinical trials include objec-
tion to be an experimental subject, or report feeling like a “guinea
pig” [29], distrust of themedical profession and a lack of knowledge
of what is required of trial participants [30]. Trials in which there
are large differences in the treatments offered, particularly in
regard to toxicity or the possibility of receiving a placebo often
experience greater recruiting difﬁculties [31]. Randomization
continues to be a concept that inﬂuences participation in research
studies and we suggest this should be a barrier addressed in
meetings with patients. Patients may feel more comfortable and
more open to enrollment with an in-depth and a clearly explained
description of randomization.
Our survey also showed, patients were highly concerned with
maintenance of privacy and safety involved with the trials. They felt
more assured and safewith the University sponsored trials. However
there were nearly a quarter of the patients who were skeptical of
their safety and privacy even with University funded clinical trials.
Past studies have conﬁrmed patient fears of safety, side effects, ef-
ﬁcacy of treatment offered and fear of placebos [32]. Studies have
reported treatment severity and worry about efﬁcacy were the top
rated fears [32]. In the recent years there has been a dramatic fall in
public trust in medical establishments and drug companies world-
wide, since unethical behavior by some violators has become visible
[33]. Trust is an important factor that affects how individuals view
clinical trials and it contributes to whether they ultimately are
willing to participate in clinical trials [34e37]. To counteract distrust
that is often felt by patients information on protection of research
subjects should be widely disseminated to the public and doctors
should clarify to patients the laws formulated to protect them.
In the past it has been argued that only reason patients would
participate in clinical trials is that they choose to be altruistic. Trials
have shown that beneﬁtting others and advancing medical
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trials [38]. Patients in our study were no different with half the
participants willing to participate in clinical trials if it helped other
patients and to advance medical progress.
Finally, in our survey industry sponsored clinical trials were not
viewed favorably when compared to the University sponsored trials.
It is difﬁcult to determine the reasons. Past studies and surveys have
explained several reasons for negative perceptions with regard to
industry conducted trials, the most dominant perception among
physicians and patients being that they skew the research they
sponsor to make their drugs look better and safer [39]. We believe
the major concern for this poor understanding is lack of knowledge
of trials conducted by pharmaceutical companies. Also our surveys
patients felt privacy and safety would be better safeguarded by the
University conducted clinical trials. Additionally despite having to
undergo frequents clinical and laboratory visits, nearly half of the
surveyed patients were willing to spend extra time and do the
additional tests required by the clinical trials.
Our study is not without limitations. Our sample size is small. As
a result we are not able to statistically segregate differences based
on gender, race, socioeconomic status, cancer type, rural vs. urban
population, religious beliefs, and the educational level. Although
we did plan a large trial, recruitment for this survey was faced with
difﬁculties. We surveyed newly diagnosed cancer patients and
hence there would have been scope for very high anxiety. We used
an unvalidated questionnaire in our survey and hence may havebeen a confounding factor in our analysis on perceptions of
randomized trials and industry run trials. These factors were
identiﬁed in literature as factors of concern when recruiting
patients for clinical trials.5. Conclusion
The common goal of the growing interest in clinical trials related
research is to increase patient accrual and accelerate the pace of
clinical research. The results of this small study suggest perhaps
that a simple straightforward solution to increase patient accrual is
not forthcoming. Our study stresses on the importance of effective
communication between physicians and patients not only to
explain study design and the beneﬁts, but also to improve accrual
rates. There are a number of areas that warrant further research and
speciﬁcally there is a need to raise community awareness about the
need for and importance of randomized clinical trials. The timing of
such education also should be the focus of research. Efforts to
improve our understanding of those factors involved and the
development of interventions to improve informed consent and
support patients in their decision making should continue.Appendix: 1
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Characteristic Frequency (n ¼ 89) %
Age Median (years) 60 ± 10
60 46 51.7
>60 43 48.3
Sex Male 46 51.7
Female 43 48.3
Race Caucasians 72 81.82
African Americans 16 18.18
Education Post graduate 5 5.68
College/Degree 30 34.09
High school 47 53.41
Middle school (grade 8) 4 4.55
Not available 2 2.27




Pancreas/others 12 13.5Appendix 3. ResultsTotal Agree (%) Neutral (%) Disagree (%) p-value
1. Drug Company trials vs government supported trials 73 26 (35.6) 34 (46.6) 34 (46.6) 0.0071
2. Promising new drug not knowing effect (phase 1) 77 28 (36.4) 21 (27.3) 28 (36.4) 0.5176
3. Information on clinical trials 78 51 (65.4) 12(15.4) 15(19.2) <0.0001
4. Randomized trials-“Flipping a coin” or “throwing a dice” 77 15 (19.5) 15 (19.5) 47 (61) <0.0001
5. Clinical trial as ﬁrst line option 76 17 (22.4) 22 (28.9) 37 (48.7) 0.0161
6. Clinical trial after ﬁrst line treatment failed 77 33 (42.9) 23 (29.9) 21 (27.3) 0.2109
7. Clinical trial for beneﬁt of others 77 33 (42.9) 25 (32.5) 19 (24.7) 0.1464
8. Participate in trials even if more time consuming or additional tests 75 30 (40) 20 (26.7) 25 (33.3) 0.3654
9. Privacy protection by the university 74 42 (56.8) 19 (25.7) 13 (17.6) <0.0001
10. Safety by University sponsored trial 74 38 (51.4) 19 (25.7) 17 (23) 0.0059References
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